At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Company Details
- Employees
- 77
- Founded
- -
- Address
- 20 Water Street, London,england E14 9gg,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.aviadobio.com
- Keywords
- Oxford.
- HQ
- London, England
Aviadobio Questions
Aviadobio's website is http://www.aviadobio.com
Aviadobio's LinkedIn profile is https://uk.linkedin.com/company/aviadobio
Aviadobio has
77 employees.
View email and phone details for 77
employees at Aviadobio.
Aviadobio's industry is
Biotechnology Research
Aviadobio's top competitors are
Bit.bio,
Touchlight,
Quell Therapeutics,
Autolus Therapeutics,
Evox Therapeutics Ltd,
Adaptimmune,
Cell And Gene Therapy Catapult,
Orchard Therapeutics - U.s.,
Achilles Therapeutics Plc,
Meiragtx.
Aviadobio's categories are Biotechnology Research
Aviadobio's founding year is 2019
